openPR Logo
Press release

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase) Pipeline Landscape and Therapeutic Assessment in H1 2017

07-05-2017 11:52 AM CET | Health & Medicine

Press release from: Pharmaceutical Research Reports [MRH]

Pharmaceutical Industry Research Reports - MRH

Pharmaceutical Industry Research Reports - MRH

According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Pipeline Review, H1 2017” has been recently broadcasted to the wide database of Market Research Hub (MRH). This report on the Aminopeptidase N market has been compiled by conducting both primary and secondary research and analyzes the market on the basis of its pipeline review.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157707

The study starts by presenting the comprehensive overview on Aminopeptidase N. his section highlights the development of therapeutics, pipeline products utilized in Aminopeptidase N, and a comparative analysis of these pipeline products. Aminopeptidase N (AP-N) or membrane alanyl aminopeptidase or alanyl aminopeptidase (AAP) is an enzyme encoded by the ANPEP gene. Aminopeptidase N or CD13 is a transmembrane protease present in a wide variety of human tissues and cell types including endothelial, epithelial, leukocyte and fibroblast. It is a multifunctional enzyme, related with tumorigenesis, immune system, pain etc. It has also analyzed that it plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. It also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides and chemokines.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157707

In the next part of the report, the therapeutics still under development by both universities and companies have been presented. Moving further, the clinical late stage and early stage products have been analyzed in this study. The drug profiles, their mechanism of action, and their research and development progress have also been encapsulated in this study.

Moving further, the key dynamics impacting the development of the Aminopeptidase N targeted therapeutics development market has also been compiled in this study. At present, Aminopeptidase N has been associated with the growth of different human cancers and suggested as a suitable target for anti-cancerous therapy. Different approaches have been used to develop new drugs directed to this target, including enzyme inhibitors as well as APN-targeted carrier constructs. Also, it has a role in angiogenesis and promotes cholesterol crystallization.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/aminopeptidase-n-myeloid-plasma-membrane-glycoprotein-cd13-or-alanyl-aminopeptidase-or-aminopeptidase-m-or-microsomal-aminopeptidase-or-gp150-or-cd13-or-anpep-or-ec-34112-pipeline-review-h1-2017-report.html

Furthermore, the study also reviews key players involved in Aminopeptidase N targeted therapeutics development with their respective active and dormant projects. The vendor landscape section of the report throws light on the companies excelling in pipeline products in the market for Aminopeptidase N. Currently, MolMed SpA, Nippon Kayaku Co. Ltd. and Pharmaleads SA are the leading companies.

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase) Pipeline Landscape and Therapeutic Assessment in H1 2017 here

News-ID: 609401 • Views:

More Releases from Pharmaceutical Research Reports [MRH]

Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled Drugs and Therapeutic Development in H1 2017
Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the First Half of 2017
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017‘’.

More Releases for Aminopeptidase

Aminopeptidase Market Growth in Future Scope 2025-2032 | MP Biomedical, Sigma-Al …
The latest report, titled "Aminopeptidase Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", published by Coherent Market Insights, offers an in-depth analysis of the industry, covering key market dynamics, competitive landscape, regional insights, and recent developments. The Aminopeptidase Market has experienced substantial growth in recent years, driven by increasing product demand, a growing customer base, and ongoing technological advancements. This report provides a detailed examination of market size,
Activated charcoal tablets Market Developments and Strategic Growth Outlook 2024 …
A new report from the WGR, titled Activated charcoal tablets Market Report 2024 Market Size, Trends, and Global Forecast 2024-2032, offers a thorough analysis of the market's changing trends, investment opportunities, and competitive landscape. By the end of 2032, the Activated charcoal tablets market trends will be valued at USD 2.46, per a WGR analysis. Furthermore, the report projects that the Activated charcoal tablets market trends will grow at a
Recombinant human albumin Market Emerging Trends, Future Growth Opportunities, a …
The Recombinant human albumin Market Report 2024 Market Size, Trends, and Global Forecast 2024-2032, a new report from the WGR, provides a comprehensive analysis of the competitive environment, investment opportunities, winning tactics, and evolving market trends. According to a WGR analysis, the Recombinant human albumin market trends will be valued at USD 4.2 (USD Billion) by the end of 2032. In addition, the report forecasts that between 2024 and 2032,
Ubenimex Market Trends, Market Share, Industry Size, Growth, Opportunities and M …
The global ubenimex market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ubenimex, also known as bestatin, is a competitive, reversible protease inhibitor and It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N, it is for use in the treatment of acute myelocytic leukemia. The increasing prevalence of chronic disease among geriatric population has created a demand for the development of new
Methionine Aminopeptidase 2 Market Revenue, Application, Outlook, Demands, Trend …
The Methionine Aminopeptidase 2 Market research report provides personalized solutions as per your needs. It also keeps you updated on the market's latest development to make robust decision-making and save time. Furthermore, the Methionine Aminopeptidase 2 Market report will allow you to tap into in-depth product knowledge and industry experience to assist in planning powerful business strategies. Moreover, the report keeps you updated on the market's developments, technological advancements, and
Latest Research Report on Global Renal Biomarker Market: Technology Innovation, …
Renal biomarkers are used in diagnosis of diseases acute or chronic kidney injuries. The renal biomarkers measure the blood and urine level, detect pre-renal, intrinsic and post renal kidney injuries. Renal Biomarker Market accounted to USD 856.7 million growing at a CAGR of 7.2% during the forecast to 2024. Get Sample of Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-renal-biomarker-market Major Market Competitors: Some of the major players operating in renal biomarker market are Abbott Laboratories, Alere Inc.,